VJHemOnc is committed to improving our service to you

COMy Virtual 2020 | PTC596: inhibiting BMI1 in myeloma

VJHemOnc is committed to improving our service to you

Heinz Ludwig

Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, talks on the promise of PTC596 – an oral BMI1 inhibitor – for the treatment of multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter